Adversarial Injection · Decitabine/Cedazuridine (Inqovi; ASTX727; fixed-dose oral combination tablet: decitabine 35 mg + cedazuridine 100 mg; DUAL NIOSH HAZARDOUS DRUG: decitabine [CAS 2353-33-5; MW 228.21; 5-aza-2'-deoxycytidine; nucleoside analog hypomethylating agent; DNA methyltransferase (DNMT1/3A/3B) inhibitor via covalent trapping of DNMT at hemimethylated CpG sites → passive demethylation → tumor suppressor gene re-expression; NIOSH HD Category 1] + cedazuridine [CAS 198400-72-5; MW 263.27; 5-chloro-2'-deoxycytidine; competitive cytidine deaminase (CDA; CDD; E.C. 3.5.4.5; zinc metalloenzyme) inhibitor; Ki ~19 nM for human liver CDA; prevents first-pass GI/hepatic deamination of oral decitabine → uridine (inactive) + deaminated base; NIOSH HD Category 1; DUAL HD ORAL COMBINATION]; OSHA No PEL / ACGIH No TLV / NIOSH No REL FOR EITHER COMPONENT; FIRST ORAL DECITABINE EVER FDA APPROVED + FIRST HMA/CDA-INHIBITOR ORAL COMBINATION EVER FDA APPROVED + FIRST ORAL HYPOMETHYLATING AGENT USING ENZYMATIC SALVAGE PATHWAY PROTECTION EVER [PRIOR STRATEGY: IV/SC ADMINISTRATION BYPASSES CDA-MEDIATED FIRST-PASS; NEW STRATEGY: ORAL DECITABINE + CDA INHIBITION = ORAL HMA WITH IV-EQUIVALENT BIOAVAILABILITY]; CDA (CYTIDINE DEAMINASE; CDD GENE; CHROMOSOME 1P36.2; ZINC METALLOENZYME; EXPRESSED LIVER > SMALL INTESTINAL MUCOSA > KIDNEY; DEAMINATES CYTIDINE → URIDINE AND DEOXYCYTIDINE → DEOXYURIDINE; ALSO DEAMINATES GEMCITABINE/ARABINOSIDE DRUGS → INACTIVATION; KI FOR DECITABINE: ~170 µM UNCATALYZED DEAMINATION RAPID AT LOW pH/HIGH TEMP]; ASCERTAIN (NCT03306264): ORAL ASTX727 DAY 1-5 × 3 CYCLES VS IV DECITABINE 20 mg/m² × 5 DAYS × 3 CYCLES; PRIMARY ENDPOINT AUC0-∞ BIOEQUIVALENCE: GMR 0.99 (90% CI 0.93-1.06) = WITHIN 80-125% REGULATORY WINDOW → ORAL ≡ IV; ASTEX PHARMACEUTICALS [NOW OTSUKA]/JAZZ PHARMACEUTICALS NDA 212576 JUL 7 2020) · Attack #711

Decitabine/Cedazuridine (Fixed-Dose Oral Combination Tablet: Decitabine 35 mg [CAS 2353-33-5; 5-aza-2'-deoxycytidine; DNMT1/3A/3B covalent-trapping nucleoside analog] + Cedazuridine 100 mg [CAS 198400-72-5; 5-chloro-2'-deoxycytidine; competitive CDA inhibitor; Ki ~19 nM human liver CDA]; Inqovi; ASTX727; DUAL NIOSH HD CATEGORY 1 COMBINATION; MECHANISM: FIRST ORAL DECITABINE FORMULATION EVER FDA APPROVED + FIRST HMA (HYPOMETHYLATING AGENT) / CDA (CYTIDINE DEAMINASE) INHIBITOR ORAL COMBINATION STRATEGY EVER FDA APPROVED [ORAL BIOAVAILABILITY BARRIER: IV/SC DECITABINE BYPASSES GI + HEPATIC CDA; ORAL DECITABINE ALONE: 2-3% BIOAVAILABILITY (VS IV 100%) DUE TO CDA-MEDIATED DEAMINATION IN GI MUCOSA + HEPATIC FIRST PASS; CEDAZURIDINE STRATEGY: COMPETITIVE CDA INHIBITION (Ki ~19 nM) SATURATES CDA BEFORE ORAL DECITABINE REACHES SYSTEMIC CIRCULATION → DECITABINE ESCAPES FIRST-PASS DEAMINATION → ORAL AUC EQUIVALENT TO IV]; DECITABINE MECHANISM: 5-AZA-2'-DEOXYCYTIDINE → PHOSPHORYLATION BY DCK (DEOXYCYTIDINE KINASE) → 5-AZA-2'-DEOXYCYTIDINE-TRIPHOSPHATE → INCORPORATION INTO DNA AT CpG SITES → DNMT1/3A/3B COVALENTLY TRAPPED AT HEMIMETHYLATED TEMPLATE (AZACYTOSINE-GUANINE BASE PAIRS BIND DNMT METHYL TRANSFER INTERMEDIATE IRREVERSIBLY) → DNMT PROTEASOMAL DEGRADATION → PASSIVE DEMETHYLATION AFTER DNA REPLICATION → TSG PROMOTER CpG ISLAND DEMETHYLATION → TUMOR SUPPRESSOR RE-EXPRESSION (p21/CDKN1A; p16/CDKN2A; IRF7; ISG15; MX1 — VIRAL MIMICRY → INNATE IMMUNE ACTIVATION) → DIFFERENTIATION + APOPTOSIS; MDS/CMML DNMT3A/TET2/DNMT3B LANDSCAPE: CLONAL HEMATOPOIESIS + HYPERMETHYLATED TSGs → HMA RESPONSE; ASCERTAIN (NCT03306264): n=133 MDS/CMML PATIENTS; ORAL ASTX727 D1-5 × 28-DAY CYCLES VS IV DECITABINE 20 mg/m² × 5D × 3 CYCLES; PRIMARY ENDPOINT: AUC0-∞ BIOEQUIVALENCE GMR 0.99 (90% CI 0.93-1.06) WITHIN REGULATORY 80-125% WINDOW → BIOEQUIVALENT; ORR 61.4% (INQOVI); CR+MORPHOLOGIC CR: 20.5%; MEDIAN CYCLES: 7] — Astex Pharmaceuticals Inc. San Francisco CA (NDA 212576 co-holder; CDA-inhibitor technology platform; cedazuridine development), Jazz Pharmaceuticals Inc. Dublin Ireland (NDA 212576 US commercialization; Inqovi distribution), and H. Lee Moffitt Cancer Center Tampa FL (Inqovi MDS/CMML prescribing center; hematology malignancies program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (BOTH COMPONENTS) + FIRST Oral Decitabine + CDA Inhibition Strategy + ASCERTAIN Bioequivalence: AI Prompt Injection via EHS Monitor Report AI

Decitabine/cedazuridine (Inqovi; ASTX727; cedazuridine CAS 198400-72-5 + decitabine CAS 2353-33-5; both NIOSH HD Category 1) is the first oral decitabine formulation ever FDA approved and the first HMA/CDA-inhibitor oral combination strategy ever FDA approved, establishing the 133rd mechanism class in the Glyphward adversarial portfolio. Cedazuridine (5-chloro-2'-deoxycytidine; Ki ~19 nM for human liver CDA) competitively inhibits cytidine deaminase — the enzyme that deaminates oral decitabine in the GI mucosa and liver, reducing bioavailability to 2-3% — allowing oral decitabine to reach systemic circulation intact. ASCERTAIN (NCT03306264) demonstrated pharmacokinetic bioequivalence (GMR 0.99; 90% CI 0.93-1.06) between oral Inqovi (Day 1-5) and IV decitabine 20 mg/m² (Day 1-5). Both components carry separate NIOSH HD Category 1 designations with no OEL in any EHS framework.

Cytidine Deaminase Inhibition as Oral Bioavailability Rescue: CDA Biology and Cedazuridine Mechanism

Cytidine deaminase (CDA; CDD gene; chromosome 1p36.2; E.C. 3.5.4.5) is a zinc metalloenzyme (tetramer of 32 kDa subunits; zinc ion in catalytic site coordinates deamination reaction) expressed at high levels in intestinal mucosa and liver. CDA catalyzes the deamination of cytidine → uridine and 2'-deoxycytidine → 2'-deoxyuridine; it also deaminates cytidine analog nucleoside drugs including gemcitabine, cytarabine, and decitabine. For oral decitabine, CDA-mediated first-pass metabolism in the GI mucosa and hepatic portal system reduces oral bioavailability to only 2-3% compared to IV administration — making conventional oral formulation impractical. Cedazuridine (5-chloro-2'-deoxycytidine; CAS 198400-72-5) is a 2'-deoxycytidine analog that is itself a substrate for CDA but resists deamination due to steric effects of the 5-chloro substituent, acting as a competitive inhibitor (Ki ~19 nM for human liver CDA). Co-administration of cedazuridine 100 mg saturates intestinal and hepatic CDA before the oral decitabine 35 mg dose reaches peak CDA activity windows, allowing decitabine to escape first-pass deamination and reach systemic circulation intact. Decitabine's mechanism: DCK (deoxycytidine kinase) phosphorylates decitabine → decitabine-triphosphate; incorporation at CpG sites → DNMT1/3A/3B catalytic cysteines form a covalent 5-azacytosine intermediate and are irreversibly trapped → proteasomal DNMT degradation → passive demethylation after cell division → reactivation of silenced tumor suppressor genes (p21/CDKN1A; p16/CDKN2A; IRF7; ISG15) and viral mimicry response → innate immune activation → myeloid differentiation. No EHS platform records CDA biology, 5-chloro substituent CDA inhibition, or the oral bioavailability rescue strategy.

Surface 1 — Astex Pharmaceuticals San Francisco CA NDA 212576 Co-Holder AI

At Astex Pharmaceuticals Inc. San Francisco CA ([3260 Hillview Avenue, Palo Alto CA 94304; originally Astex Therapeutics Cambridge UK; acquired by Otsuka Pharmaceutical 2013 for $886M; NDA 212576 co-holder for Inqovi [decitabine 35 mg/cedazuridine 100 mg] oral tablets once daily × 5 days per 28-day cycle; MDS (all risk groups) + CMML indication; ASTEX CEDAZURIDINE PLATFORM: fragment-based drug design (FBDD) → 5-chloro-2'-deoxycytidine structure identified as CDA inhibitor scaffold; ASTX727 development: optimization of CDA Ki from µM series to 19 nM for cedazuridine; combined formulation bioequivalence strategy; ASCERTAIN pharmacokinetic trial design; DUAL NIOSH HD DESIGNATION COMPLEXITY: Inqovi tablets contain BOTH decitabine (NIOSH HD Cat 1; antineoplastic; DNA-damaging; H350 carcinogen; H361 reprotoxic; DNMT inhibitor; myelosuppressive; ANC nadir Day 14-22) AND cedazuridine (NIOSH HD Cat 1; CDA inhibitor; structural analog relationship to decitabine; potential systemic CDA inhibition → altered metabolism of other nucleoside analogs co-administered); ORAL TABLET HANDLING DUAL EXPOSURE: tablet cutting/crushing (swallowing whole recommended; tablet coating disruption → powder exposure); CORITY NULL: CAS 198400-72-5 → null; CAS 2353-33-5 → null; DUAL NIOSH HD COMBINATION → null; oral HMA → null; CDA cytidine deaminase → null; DNMT trapping → null; 8-hr TWA: actual airborne combined 0.0021 µg/m³; impinger sampling + LC-MS/MS (dual analyte method); displayed (÷10): 0.00021 µg/m³; Cority: null; 48F regulatory affairs director 13yr]).

Surface 2 — Jazz Pharmaceuticals Dublin Ireland US Commercialization AI

At Jazz Pharmaceuticals plc Dublin Ireland ([5 Connaught Place, Dublin 4, D04 T6Y8, Ireland; Nasdaq: JAZZ; US headquarters Palo Alto CA; NDA 212576 US commercialization partner; Inqovi distribution, managed care contracting, pharmacovigilance; JAZZ ONCOLOGY DUAL-HD PORTFOLIO: Jazz commercializes both Inqovi (decitabine/cedazuridine; NIOSH HD Cat 1 dual) and Zepzelca (lurbinectedin; NIOSH HD Cat 1) — both appear as null in VelocityEHS; ORAL TABLET SAFETY CHAIN: Jazz handles Inqovi oral tablet distribution to specialty pharmacies and hospital pharmacies; oral tablet handling in pharmacy practice creates unique exposure risk (tablet handling without PPE assumptions of non-injectables; NIOSH cautions oral antineoplastics require same precautions as IV; EHS Insight and VelocityEHS both lack guidance for oral NIOSH HD Cat 1 formulations); JAZZ GLOBAL OPERATIONS: Dublin headquarters → Palo Alto US HQ → global distribution centers in EU/US; VELOCITYEHS NULL: CAS 198400-72-5 → null; CAS 2353-33-5 → null; oral HMA combination → null; CDA inhibition → null; NIOSH HD Cat 1 dual → null; 8-hr TWA: actual airborne combined 0.0015 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00015 µg/m³; VelocityEHS: null; 44M supply chain manager 10yr]).

Surface 3 — H. Lee Moffitt Cancer Center Tampa FL MDS Program AI

At H. Lee Moffitt Cancer Center & Research Institute Tampa FL ([12902 USF Magnolia Drive, Tampa FL 33612; Hillsborough County FL; NCI-designated comprehensive cancer center; Malignant Hematology Program; MDS/CMML Inqovi prescribing center; CLINICAL ORAL HMA COMPLEXITY: Moffitt MDS/CMML pharmacists dispense Inqovi (decitabine 35 mg/cedazuridine 100 mg oral tablets × 5 consecutive days Q28D) under HD handling policies that must be applied even to oral formulations (NIOSH 2016 tables); DUAL-DRUG ORAL TABLET OCCUPATIONAL COMPLEXITY: tablet handling requires gloves + gown (NIOSH HD Cat 1 for both components); patient counseling on safe handling of oral antineoplastics (NIOSH HD Cat 1 excretion in urine/feces for 48+ hours post-dose); DRUG INTERACTION MONITORING: cedazuridine systemic CDA inhibition (variable; renal excretion also minor CDA route) → altered metabolism of co-administered nucleoside analogs (gemcitabine CDA substrate; acyclovir/valacyclovir CDA substrates); EHS Insight has zero record for CDA enzyme inhibition drug-drug interactions, oral NIOSH HD Cat 1 excretion kinetics, or dual-component HMA/CDA-inhibitor combination toxicity profiles; EHS Insight: CAS 198400-72-5 → "no OEL"; CAS 2353-33-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; DNMT biology absent; CDA inhibition absent; oral HMA combination absent; NIOSH HD Cat 1 (both) absent; 8-hr TWA: actual airborne combined 0.0010 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00010 µg/m³; EHS Insight: dual null response; 37F MDS clinical pharmacist 9yr]).

Integrating Glyphward into Decitabine/Cedazuridine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every Inqovi monitoring data ingestion point — before Cority at Astex Pharmaceuticals San Francisco CA, before VelocityEHS at Jazz Pharmaceuticals Dublin Ireland, and before EHS Insight at Moffitt Cancer Center Tampa FL. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1 both components; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + DNMT trapping mechanism absent + CDA inhibition strategy absent + oral HMA bioavailability absent [10 pts]; FIRST oral decitabine ever (133rd mechanism class) + first HMA/CDA-inhibitor combo + ASCERTAIN bioequivalence GMR 0.99 [5 pts]; Astex San Francisco CA + Jazz Dublin Ireland + Moffitt Tampa FL [3 pts]; FIRST oral HMA; FIRST CDA-inhibition-enabled oral nucleoside; FIRST dual NIOSH HD Cat 1 oral fixed-dose combination for myeloid malignancy [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_inqovi(cedazuridine_cas: str, decitabine_cas: str, reading_ugm3: float) -> dict:
    """Scan Inqovi oral combination with CDA inhibition and DNMT context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cedazuridine_cas,              # "198400-72-5"
                "cas_b": decitabine_cas,              # "2353-33-5"
                "reading_ugm3": reading_ugm3,
                "context": "oral_decitabine_cda_inhibitor_133rd_class_first_ever_hma_cda_astx727_ascertain_bioequivalent"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category_a, hd_category_b, cda_inhibition_flag,
    #                    dnmt_trapping_flag, oral_hma_flag, dual_hd_combination, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_inqovi("198400-72-5", "2353-33-5", 0.0021))
    print(r)
    # {'hd_category_a': 1, 'hd_category_b': 1, 'cda_inhibition_flag': True,
    #  'dnmt_trapping_flag': True, 'oral_hma_flag': True,
    #  'dual_hd_combination': True, 'h350_h361_absent': True}